Annual Total Expenses
$34.09 M
-$24.96 M-42.27%
March 31, 2024
Summary
- As of February 8, 2025, VTGN annual total expenses is $34.09 million, with the most recent change of -$24.96 million (-42.27%) on March 31, 2024.
- During the last 3 years, VTGN annual total expenses has risen by +$15.06 million (+79.17%).
- VTGN annual total expenses is now -42.27% below its all-time high of $59.04 million, reached on March 31, 2023.
Performance
VTGN Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Expenses
$14.41 M
+$2.19 M+17.97%
September 30, 2024
Summary
- As of February 8, 2025, VTGN quarterly total expenses is $14.41 million, with the most recent change of +$2.19 million (+17.97%) on September 30, 2024.
- Over the past year, VTGN quarterly total expenses has stayed the same.
- VTGN quarterly total expenses is now -28.25% below its all-time high of $20.08 million, reached on June 30, 2022.
Performance
VTGN Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Expenses Formula
Total Expenses = Cost of Goods Sold + Operating Expenses + Non Operating Expenses
VTGN Total Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -42.3% | 0.0% |
| 3 y3 years | +79.2% | 0.0% |
| 5 y5 years | +39.0% | 0.0% |
VTGN Total Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -42.3% | +79.2% | -28.3% | +104.2% |
| 5 y | 5-year | -42.3% | +79.2% | -28.3% | +361.5% |
| alltime | all time | -42.3% | >+9999.0% | -28.3% | >+9999.0% |
VistaGen Therapeutics Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $14.41 M(+18.0%) |
| Jun 2024 | - | $12.21 M(+5.7%) |
| Mar 2024 | $34.09 M(-42.3%) | $11.56 M(+39.3%) |
| Dec 2023 | - | $8.30 M(+17.5%) |
| Sep 2023 | - | $7.06 M(-1.6%) |
| Jun 2023 | - | $7.17 M(-42.2%) |
| Mar 2023 | $59.04 M(+21.3%) | $12.42 M(+24.8%) |
| Dec 2022 | - | $9.95 M(-40.1%) |
| Sep 2022 | - | $16.60 M(-17.4%) |
| Jun 2022 | - | $20.08 M(+20.0%) |
| Mar 2022 | $48.66 M(+155.8%) | $16.73 M(+53.5%) |
| Dec 2021 | - | $10.90 M(-17.2%) |
| Sep 2021 | - | $13.16 M(+67.2%) |
| Jun 2021 | - | $7.87 M(+18.1%) |
| Mar 2021 | $19.02 M(-4.8%) | $6.66 M(+18.7%) |
| Dec 2020 | - | $5.61 M(+54.7%) |
| Sep 2020 | - | $3.63 M(+16.2%) |
| Jun 2020 | - | $3.12 M(-4.3%) |
| Mar 2020 | $19.97 M(-18.6%) | $3.26 M(-36.5%) |
| Dec 2019 | - | $5.14 M(-4.0%) |
| Sep 2019 | - | $5.35 M(-14.0%) |
| Jun 2019 | - | $6.22 M(+8.8%) |
| Mar 2019 | $24.53 M(+76.4%) | $5.72 M(-20.2%) |
| Dec 2018 | - | $7.17 M(-3.6%) |
| Sep 2018 | - | $7.43 M(+76.5%) |
| Jun 2018 | - | $4.21 M(-22.1%) |
| Mar 2018 | $13.91 M(+25.6%) | $5.40 M(+108.5%) |
| Dec 2017 | - | $2.59 M(-45.1%) |
| Sep 2017 | - | $4.71 M(+108.5%) |
| Jun 2017 | - | $2.26 M(-11.3%) |
| Mar 2017 | $11.07 M(-5.9%) | $2.55 M(-27.6%) |
| Dec 2016 | - | $3.52 M(+14.1%) |
| Sep 2016 | - | $3.08 M(+60.3%) |
| Jun 2016 | - | $1.92 M(-78.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2016 | $11.77 M(+73.6%) | $8.93 M(+316.8%) |
| Dec 2015 | - | $2.14 M(-60.2%) |
| Sep 2015 | - | $5.39 M(+217.1%) |
| Jun 2015 | - | $1.70 M(-48.2%) |
| Mar 2015 | $6.78 M(+40.5%) | $3.28 M(+193.5%) |
| Dec 2014 | - | $1.12 M(+0.3%) |
| Sep 2014 | - | $1.11 M(-12.4%) |
| Jun 2014 | - | $1.27 M(+22.9%) |
| Mar 2014 | $4.82 M(-31.0%) | $1.03 M(-16.7%) |
| Dec 2013 | - | $1.24 M(+2.2%) |
| Sep 2013 | - | $1.21 M(-9.0%) |
| Jun 2013 | - | $1.33 M(-30.2%) |
| Mar 2013 | $6.99 M(-28.2%) | $1.91 M(-0.4%) |
| Dec 2012 | - | $1.92 M(+14.3%) |
| Sep 2012 | - | $1.68 M(+13.0%) |
| Jun 2012 | - | $1.49 M(-54.4%) |
| Mar 2012 | $9.74 M(>+9900.0%) | $3.26 M(+47.1%) |
| Dec 2011 | - | $2.21 M(+4.3%) |
| Sep 2011 | - | $2.12 M(-1.5%) |
| Jun 2011 | - | $2.15 M(>+9900.0%) |
| Mar 2011 | - | $5300.00(+178.9%) |
| Dec 2010 | $8900.00(-59.5%) | $1900.00(-9.5%) |
| Sep 2010 | - | $2100.00(0.0%) |
| Jun 2010 | - | $2100.00(-25.0%) |
| Mar 2010 | - | $2800.00(+100.0%) |
| Dec 2009 | $22.00 K(+34.1%) | $1400.00(+7.7%) |
| Sep 2009 | - | $1300.00(-38.1%) |
| Jun 2009 | - | $2100.00(-87.8%) |
| Mar 2009 | - | $17.20 K(+32.3%) |
| Dec 2008 | $16.40 K | $13.00 K(>+9900.0%) |
| Sep 2008 | - | $100.00(-90.9%) |
| Jun 2008 | - | $1100.00(-50.0%) |
| Mar 2008 | - | $2200.00(-4.3%) |
| Jun 2007 | - | $2300.00(+4.5%) |
| Mar 2007 | - | $2200.00 |
FAQ
- What is VistaGen Therapeutics annual total expenses?
- What is the all time high annual total expenses for VistaGen Therapeutics?
- What is VistaGen Therapeutics annual total expenses year-on-year change?
- What is VistaGen Therapeutics quarterly total expenses?
- What is the all time high quarterly total expenses for VistaGen Therapeutics?
- What is VistaGen Therapeutics quarterly total expenses year-on-year change?
What is VistaGen Therapeutics annual total expenses?
The current annual total expenses of VTGN is $34.09 M
What is the all time high annual total expenses for VistaGen Therapeutics?
VistaGen Therapeutics all-time high annual total expenses is $59.04 M
What is VistaGen Therapeutics annual total expenses year-on-year change?
Over the past year, VTGN annual total expenses has changed by -$24.96 M (-42.27%)
What is VistaGen Therapeutics quarterly total expenses?
The current quarterly total expenses of VTGN is $14.41 M
What is the all time high quarterly total expenses for VistaGen Therapeutics?
VistaGen Therapeutics all-time high quarterly total expenses is $20.08 M
What is VistaGen Therapeutics quarterly total expenses year-on-year change?
Over the past year, VTGN quarterly total expenses has changed by $0.00 (0.00%)